Starling Oncology, Inc. (NASDAQ:STLNW)
| Market Cap | 4.42M-9.8% |
| Revenue (ttm) | 587.24M+38.4% |
| Net Income | -36.29M+44.9% |
| EPS | -0.30+55.8% |
| Shares Out | 99.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,505 |
| Open | 0.05 |
| Previous Close | 0.05 |
| Day's Range | 0.04 - 0.05 |
| 52-Week Range | 0.04 - 0.05 |
| Beta | 2.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About STLNW
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
$STLNW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in STLNW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by STLNW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
STLNW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New STLNW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to STLNW from public contracts
Source: USAspending.gov
STLNW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from STLNW’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.
